ots ML, Elwood PC, Nikitin Y, Salonen JT, Freire de Concalves A,
Inzitari D, et al. Total and HDL cholesterol and risk of stroke.
EUROSTROKE: a collaborative study among research centres in
Europe. J Epidemiol Comm Health 2002;56(suppl 1):i19-24.
116. Horenstein RB, Smith DE, Mosca L. Cholesterol predicts stroke
mortality in the women’s Pooling Project. Stroke 2002;33:1863-8.
117. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et
al. Efficacy and safety of cholesterol-lowering treatment: prospective
meta-analysis of data from 90,056 participants in 14 randomised trials
of statins. Lancet 2005;366:1267-78.
118. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGCoA Reductase
Inhibitors on stroke. A meta-analysis of randomized, controlled trials.
Ann Intern Med 1998;128:89-95.
119. Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE,
Callahan A 3rd, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack:
the Stroke Prevention by Aggressive Reduction in cholesterol Levels
(SPARCL) trial. Stroke 2007;38:3198-204.
120. Crouse JR 3rd, Grobbee DE, O’Leary DH, Bots ML, Evans GW,
Palmer MK, et al. Measuring Effects on intima media Thickness: an
Evaluation Of Rosuvastatin in subclinical atherosclerosis–the rationale
and methodology of the METEOR study.. Cardiovasc Drugs Ther
2004;18:231-8.

JOURNAL OF VASCULAR SURGERY
Volume 54, Number 3

121. Taylor AJ, Kent SM, Flaherty PJ